优化临床试验设计和决策心力衰竭与保存的喷射小部分 (HFpEF):基于安慰剂反应模型的元分析
Xiaoya Chen1, Juan Yang1, Ling Xu1
1Center for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Cardiovascular therapeutics
|October 15, 2025
概括
一个新的安慰剂反应模型有助于心力衰竭与保存的喷射分数 (HFpEF) 试验. 该模型优化了样本大小,并使用住院和6分钟步行距离等关键指标评估药物疗效.
科学领域:
- 心脏病学 心脏病学
- 临床试验 临床试验
- 生物统计学 生物统计学
背景情况:
- 保存喷射分数 (HFpEF) 的心力衰竭在临床试验设计中提出了挑战.
- 准确估计安慰剂反应对于优化试验样本大小和解释疗效数据至关重要.
研究的目的:
- 开发一个强大的安慰剂反应模型,用于HFpEF临床试验中的关键疗效指标.
- 为了促进更好的样本大小估计和试验优化策略.
主要方法:
- 对安慰剂控制的HFpEF试验进行系统的文献搜索.
- 在安慰剂组中基于模型的心血管死亡,心力衰竭住院和6分钟步行距离 (6MWD) 的元分析 (MBMA).
- 在各种场景下模拟安慰剂效应分布.
主要成果:
- 对29项涉及14302名参与者的研究进行了分析.
- 开发了事件率的日志正常风险函数和6MWD变化的线性模型.
- 模拟1年事件率:复合 (心脏病死亡/心脏病死亡) 的11.1%,心脏病死亡的10.5%,所有原因死亡的2.91%,心脏病死亡的2.33%.
- 在1,3,6个月的典型6MWD变化分别为1.47m,4.76m和9.57m.
- 使用复合事件减少了500-12,000个病例的样本大小; 548个病例足以产生6MWD变化.
结论:
- 已建立的安慰剂反应模型支持HFpEF试验的样本大小估计.
- 该模型有助于优化临床试验设计和评估药物疗效.
- 作为评估诸如Sacubitril/Valsartan和运动训练等干预措施的外部控制的证明.
相关概念视频
01:30Heart Failure V: Medical Management
218
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
218
01:30Heart Failure IV: Classification and Diagnostic Evaluation
319
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
319
01:22Heart Failure Drugs: β-Blockers
770
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
770
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
932
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
932
01:22Heart Failure VI: Adjunct Therapies
255
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
255
01:17Pathophysiology of Heart Failure
2.9K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.9K